| The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. | |
| | |
MedLine Citation:
|
PMID: 23331559 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: GSK2190915, a potent 5-lipoxygenase-activating protein inhibitor, prevents the synthesis of leukotrienes and 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE). OBJECTIVE: To assess the effect of GSK2190915 on the allergen-induced asthmatic responses. METHODS: Nineteen eligible male subjects with mild asthma were enrolled in and completed this four-centre, double-blind, two-way crossover study (ClinicalTrials.gov NCT00748306). Subjects took GSK2190915 100 mg and placebo orally once daily for 5 days in randomized order. On Day 1 and 4 they had a methacholine challenge, on Day 3 they had an inhaled allergen challenge, and on Days 4 and 6 they had sputum induction. RESULTS: GSK2190915 attenuated the early (0-2 h) and late (4-10 h) asthmatic responses to inhaled allergen compared with placebo. There was a statistically significant attenuation of the early asthmatic response (EAR) by GSK2190915; treatment difference of GSK2190915 vs. placebo for the minimum FEV(1) EAR was 0.408 L (0.205, 0.611). There was a statistically significant attenuation of the late asthmatic response (LAR) by GSK2190915; the treatment difference of GSK2190915 vs. placebo for the minimum FEV(1) LAR was 0.229 L (0.041, 0.417). There was a statistically significant attenuation of allergen-induced sputum eosinophil count on Day 4 following GSK2190915: mean treatment difference (95% CI) between GSK2190915 and placebo was -9.95% (-18.15%, -1.77%). Compared with placebo, GSK2190915 100 mg reduced median sputum LTB(4) by > 90% on Days 4 and 6. There was no effect on methacholine PC(20) post allergen. GSK2190915 was generally well tolerated. CONCLUSION AND CLINICAL RELEVANCE: GSK2190915 shows potential as a treatment for patients with asthma. |
| | |
Authors:
|
S E Kent; M Boyce; Z Diamant; D Singh; B J O'Connor; P S Saggu; V Norris |
Related Documents
:
|
21036509 - Adapting problem-solving therapy for depressed older adults in methadone maintenance tr... 3310529 - Restricted environmental stimulation therapy of smoking: a parametric study. 15876899 - A double-blind placebo-controlled trial of bupropion sustained-release for smoking cess... 17999769 - The mental status of 1090 heroin addicts at entry into treatment: should depression be ... 15223089 - Adding a nicotine blocking agent to cigarette tapering. 20636659 - Lifetime multiple substance use pattern among heroin users before entering methadone ma... 8306739 - The effect of exogenous surfactant therapy on lung function following cardiopulmonary b... 19628959 - Cognitive therapy versus rogerian supportive therapy in borderline personality disorder... 20553629 - An evaluation of the hypolipidemic effect of an extract of hibiscus sabdariffa leaves i... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology Volume: 43 ISSN: 1365-2222 ISO Abbreviation: Clin. Exp. Allergy Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-01-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8906443 Medline TA: Clin Exp Allergy Country: England |
Other Details:
|
Languages: eng Pagination: 177-86 Citation Subset: IM |
Copyright Information:
|
© 2012 Blackwell Publishing Ltd. |
Affiliation:
|
GlaxoSmithKline, London, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts.
Next Document: Segmental allergen challenge enhances chitinase activity and levels of CCL18 in mild atopic asthma.